When anti-PD1 monoclonal antibodies were first developed, the physiopathological basis that was supposed to be behind their efficacy was that the removal of the inhibitory signal coming from the PD-1/PD-L1 axis would rescue CD8+ T cells from their exhausted state, eliciting a direct killer response against the tumour. This evidence concerns the gene CD274 and neoplasm.